ALD 301

Drug Profile

ALD 301

Alternative Names: ALD-301

Latest Information Update: 31 Aug 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Aldagen
  • Developer Aldagen; National Heart, Lung and Blood Institute; University of Texas Health Science Center at Houston
  • Class Stem cell therapies
  • Mechanism of Action Angiogenesis inducing agents; Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Peripheral arterial occlusive disorders

Most Recent Events

  • 31 Aug 2016 ALD 301 is still in phase II trials for Peripheral arterial occlusive disorders in USA (IM)
  • 13 Nov 2014 Cytomedix changes name to Nuo Therapeutics
  • 31 Mar 2014 ALD 301 is available for licensing as of 31 Mar 2014. http://www.cytomedix.com/
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top